Here's Why Grail Stock Soared Higher This Week

By Lee Samaha – Mar 26, 2026 at 2:01PM ESTKey PointsInvestors are hoping follow-up trial data will validate Grail's Galleri test.The failure to meet a trial's primary endpoint could be due to how the trial was designed rather than the efficacy of the Galleri test. Shares in multi-cancer early detection (MCED) test company Grail (GRAL 1.15%) rose by 11.4% in the week to Thursday, 1 p.m. The move comes as analysts warm to the stock's risk/reward proposition. A speculative healthcare stock High risk and high reward are definitely how investors should think about this stock. The stock declined sharply in February on news that it missed its primary endpoint in a 3-year period and in a 142,000-person demographic trial of its Galleri MCED test with England's National Health Service. Image source: Getty Images. Normally, that would be enough to walk away from the notion that the test would receive Food and Drug Administration (FDA) approval, let alone insurance coverage. For reference, the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act in January has created a pathway through which MCED screenings can be covered by Medicare once they receive FDA approval.

Why Wall Street is warming to Grail Despite failing to meet the primary endpoint of demonstrating a statistically significant reduction in Stage III and Stage IV (combined) cancers in the test group, Galleri did detect substantially more Stage I and Stage II cancers in the test group than in the control group. ExpandNASDAQ: GRALGrailToday's Change(-1.15%) $-0.60Current Price$51.69Key Data PointsMarket Cap$2.1BDay's Range$50.70 - $53.4452wk Range$20.44 - $118.84Volume350KAvg Vol1.3MGross Margin-5295.44% Moreover, there's reason to believe that follow-up data from the trial may well demonstrate its efficacy, and management is pursuing FDA approval. Speaking on the earnings call in February, CEO Bob Ragusa noted that the trial was designed six years ago and "we probably should have allowed for a longer follow-up period." The expectation is that the data from the follow-up period of up to 12 months will show a natural increase in cancers in the control group, thereby demonstrating that Galleri screening reduces late-stage cancer diagnoses. Such thinking encouraged TD Cowen to upgrade the stock recently, and this week, Guggenheim reiterated a buy rating and its $130 price target. The stock remains a risky proposition, but it also offers rewards that might attract risk-seeking investors. Read NextMar 22, 2026 •By Jonathan PoncianoThis Investor Exited a $22 Million GRAIL Stake Before a 50% One-Day Stock Crash Last MonthMar 21, 2026 •By Lee SamahaHere's Why Grail Shares Crushed the Market This WeekMar 11, 2026 •By Lee SamahaHere's Why Grail Shares Crashed in February and Why it Could Be a Buying OpportunityFeb 24, 2026 •By Lee SamahaHere's Why Grail Stock Bounced Back 16% TodayMar 25, 2026 •By Prosper Junior BakinyIs Pfizer Stock a Buy After This Win?Mar 26, 2026 •By Brett SchaferJensen Huang Just Delivered Incredible News for Investors of This Technology StockAbout the AuthorLee Samaha is a contributing Stock Market Analyst at The Motley Fool covering industrials, electricals, energy, materials, transportation, and infrastructure stocks. Prior to The Motley Fool, Lee was a Civil Engineer and Investment Manager. He holds a Bachelor of Civil and Structural Engineering from Southampton University and a Certificate in Investment Management from Chartered Institute for Securities & Investment. Lee first cut his investing teeth on The Motley Fool bulletin boards (commonly referred to as the “Fool Boards,”) and he’s infinitely grateful to all of the investors he learned from in this powerful investing community.TMFSaintGermainX@LeeSamahaStocks MentionedGrailNASDAQ: GRAL$51.69(-1.15%)-$0.60*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.